Predictively consistent prior effective sample sizes
Beat E. Neuenschwander, Sebastian Weber, Heinz Schmidli et al. · Biometrics · 2020
Determining the sample size of an experiment can be challenging, even more so when incorporating external information via a prior distribution. Such information is increasingly used to reduce the size of the control group in randomized clinical trials. Knowing the amount of prior information, expressed as an equivalent prior effective sample size (ESS), clearly facilitates trial designs. Various methods to obtain a prior's ESS have been proposed recently. They have been justified by the fact that they give the standard ESS for one-parameter exponential families. However, despite being based on similar information-based metrics, they may lead to surprisingly different ESS for nonconjugate settings, which complicates many designs with prior information. We show that current methods fail a basic predictive consistency criterion, which requires the expected posterior-predictive ESS for a sample of size N to be the sum of the prior ESS and N. The expected local-information-ratio ESS is introduced and shown to be predictively consistent. It corrects the ESS of current methods, as shown for normally distributed data with a heavy-tailed Student-t prior and exponential data with a generalized Gamma prior. Finally, two applications are discussed: the prior ESS for the control group derived from historical data and the posterior ESS for hierarchical subgroup analyses.
Cited by 80 works. doi:10.1111/biom.13252 Open-access PDF
Authors
References
- Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper)
- Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
- Clinical pharmacology and therapeutics
- Prior distributions for variance parameters in hierarchical models
- The combination of randomized and historical controls in clinical trials
- Power prior distributions for regression models
- NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- On Outlier Rejection Phenomena in Bayes Inference
- Approximating Priors by Mixtures of Natural Conjugate Priors